Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation
Samantha K. Bartholomew, Julie Turk, Wendy Winslow, Christopher Foley, Arthur Y. Shaw, Samantha Rokey, Savannah Tallino, Jessica M. Judd, Thomas G. Beach, Geidy E. Serrano, Gerrit Wilms, Ragini Kushwaha, Aidan McMahon, Sean Brendan Ginn, Walter B. Becker, , Ramón Velázquez
This study shows that inhibiting Dyrk1a with the compound DYR533 reduces tau pathology, neuroinflammation, and amyloidosis in mouse models of neurodegenerative diseases.
bioRxiv · Jan 23, 2026 · PreprintNeuroscience